Company: HCTI
Filing Date: 2025-04-22
Form Type: S-1/A
Source: 0001213900-25-034248
Chunk: 39

Company: Healthcare Triangle, Inc.
Filing Date: 2025-04-22
Form: S-1/A
Chunk 39
---
 Common Stock (the “Conversion Shares”) at an initial conversion price equal to $3.44688,
provided that if an event of default has occurred and is continuing without cure, the conversion price will be the lesser of (i) $3.44688,
(ii) 95% of the average of the three lowest daily volume weighted average prices of the Common Stock during the 20 trading days immediately
preceding the notice of conversion of the Note, and (iii) 80% of the lowest daily volume weighted average price in the 10 trading days
immediately preceding the applicable conversion date, subject to adjustment as further specified in the Note. Each Note is fully repayable
in cash upon maturity. In addition, the Investor has the option of requiring prepayment of up to 25% of the issuance amount of a subsequent
financing.

The Warrants are exercisable at an initial exercise
price of $3.44688 per share, subject to adjustment. The Warrants carry a 5-year term and, if not exercised, will terminate on December
28, 2028.

The securities were issued and sold in reliance
upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated
thereunder since, among other things, the issuance was made without any public solicitation to a limited number of accredited investors
and/or qualified institutional buyers and were acquired for investment purposes only.

Issuances of Common Stock

We issued 393,000 shares of common stock (the
“Shares”), a Pre-Funded Warrant (the “Pre-Funded Warrant”) to purchase up to an aggregate of 216,756 shares of
the Company’s common stock (the “Warrant Shares”) and Preferred Investment Options (the “Preferred Investment
Options”) to purchase up to an aggregate of 609,756 shares of common stock (the “PIO Shares” and together with the Shares,
Pre-Funded Warrant and the Warrant Shares, the “Securities”) pursuant to the terms and conditions of the Securities Purchase
Agreement, dated as of July 10, 2022, between us and a single purchaser. In addition to this, in connection with this offering, we also
issued to the Placement Agent, or its designees, Placement Agent Preferred Investment Options to purchase up to an aggregate of 42,683
shares of the Company’s common stock.

The issuance of the